Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD

Next Previous
X
Search
Trial Profile

Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Interstitial lung diseases
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche; Roche Farma

    • Most Recent Events

    • 22 Dec 2021 Results of subgroup analysis assessing the effects of immunomodulators (concomitant mycophenolate mofetil [MMF]and/or previous corticosteroids) with pirfenidone in patients with uILD published in the Advances in Therapy
    • 21 Jan 2021 According to a Genentech media release, U.S. Food and Drug Administration (FDA) has accepted the companys supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). The FDA is expected to make a decision on approval by May 2021.The sNDA is based on results from this trial.
    • 20 May 2020 Results (n=45) of subgroup analysis evaluating benefit from pirfenidone stratified by concomitant Mycophenolate Mofetil (MMF) Use, presented at the 116th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top